TICKERNERD
Menu
XENEXENEHealthcare · Biotechnology

XENE Stock Forecast: Xenon Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Aug 2026
$63
−1.60% on the day

The 20 Wall Street analysts covering Xenon Pharmaceuticals, Inc. hold a median 12-month price target of $80 — +26.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 11 Aug 2026 — in the upper half.

Market cap
$6.1B
Ticker Nerd rank
51 / 100
Median analyst target
$80
Analysts covering
20
Total return, dividends reinvested
1W
−1.3%
1M
−8.3%
YTD
+41.0%
1Y
+85.3%
From 52W high
−10.9%
From 52W low
+85.3%
$34
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XENE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xenon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Aug 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
93
Momentum
83
Revisions
67
Value
66
Quality
46
Issuance
40
Accruals
37
Growth
29
Size
21

Volatility (93): The share price has been relatively steady.

Growth (29): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (21): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs trader with fifteen years in markets.

Wall Street

XENE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XENE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Oct 25Jan 26Apr 26Jul 26XENEHigh $100Median $80Low $69

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says20 analysts
20 Buy0 Hold0 Sell
Low $69Median $80High $100

The green dot is the last close — the median target sits +26.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsOutperform$82 → $81
27 May 2026JP MorganMaintainsOverweight$80 → $82
27 May 2026JP MorganMaintainsOverweight—
12 May 2026JP MorganMaintainsOverweight—
8 May 2026NeedhamMaintainsBuy—
8 May 2026RBC CapitalMaintainsOutperform—
16 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Deutsche BankMaintainsBuy—
10 Mar 2026HC Wainwright & Co.MaintainsBuy—
10 Mar 2026WedbushMaintainsOutperform—
10 Mar 2026Wells FargoMaintainsOverweight—
9 Mar 2026BairdMaintainsOutperform—
9 Mar 2026NeedhamMaintainsBuy—
27 Feb 2026NeedhamMaintainsBuy—
27 Feb 2026Wells FargoMaintainsOverweight—
24 Feb 2026Wolfe ResearchInitiatesOutperform—
9 Jan 2026JP MorganMaintainsOverweight—
11 Dec 2025Wells FargoMaintainsOverweight—
18 Nov 2025JP MorganMaintainsOverweight—
4 Nov 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XENE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

XENE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
7
Fundamentals

Xenon Pharmaceuticals, Inc. (XENE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.5×

Cheaper than 94% of US stocks

Price / sales
816.6×

Cheaper than 1% of US stocks

Price / book
8.7×

Cheaper than 12% of US stocks

EV / EBITDA
−11.9×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−4974.3%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−43.6%

Higher than 23% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

XENE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XENEXenon Pharmaceuticals, Inc.$6.1B
51
PTCTPTC Therapeutics, Inc.$6.1B
71
DNTHDianthus Therapeutics, Inc.$5.9B
59
ERASErasca, Inc.$6.3B
68
SRRKScholar Rock Holding Corp.$6.3B
30
MIRMMirum Pharmaceuticals, Inc.$6.4B
70
LGNDLigand Pharmaceuticals, Inc.$5.7B
73

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xenon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XENE news & analysis

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity

Seeking Alpha · 11 Aug 2026positive

Xenon Pharmaceuticals was upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures. The company plans an NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion, and phase 3 X-NOVA2 topline data for major depressive disorder expected in 1H 2027.

Why it matters — A XENE watcher would care because positive phase 3 results and the planned NDA filing for azetukalner, along with upcoming MDD data, mark key clinical and regulatory milestones for the company's pipeline.

Xenon Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

The excerpt reports on 10x Genomics' second-quarter earnings, with revenue of $151 million including $1.6 million in license and royalty revenue from its Takara Bio settlement. Excluding non-recurring settlement revenue, revenue was $149.4 million, up 3% from the prior-year quarter.

Why it matters — Although the headline references Xenon Pharmaceuticals, the excerpt actually covers 10x Genomics' results, so a XENE watcher would find this item unrelated to Xenon's own performance.

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

Zacks Investment Research · 7 Aug 2026positive

Xenon Pharmaceuticals reported a narrower-than-expected loss for Q2, with sales at nil, as its lead candidate azetukalner advances toward a planned FDA filing. The company's cash runway is expected to support operations into 2029.

Why it matters — A XENE watcher would care because the narrower loss, ongoing pipeline progress toward an FDA filing, and cash runway through 2029 point to the company's financial health and key development milestone.

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Xenon Pharmaceuticals Inc. (XENE) held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The item reports the call's occurrence and provides access to the full transcript.

Why it matters — A XENE watcher would care because the earnings call transcript offers direct insight into the company's recent quarterly results and management commentary.

Xenon Reports Q2 2026 Financial Results and Provides Business Update

GlobeNewsWire · 6 Aug 2026positive

Xenon Pharmaceuticals reported Q2 2026 financial results and provided a business update, stating that the NDA submission for azetukalner remains on track for Q3 2026 following a pre-NDA meeting with the FDA. The company noted continued enrollment in multiple Phase 3 studies, expected topline data from its X-NOVA2 MDD study in H1 2027, Phase 1 studies advancing for pain candidates, and a cash position of $1.2 billion supporting a runway into 2029.

Why it matters — XENE watchers would care because the company affirms its azetukalner NDA submission timeline and highlights a strong cash runway into 2029 alongside continued advancement across its pipeline.

FAQ

Frequently asked questions about XENE stock

What is the XENE stock price forecast for 2026-2027?

The 20 Wall Street analysts covering Xenon Pharmaceuticals, Inc. have a median 12-month price target of $80, with estimates ranging from $69 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XENE stock a buy right now?

Of the 20 analysts covering Xenon Pharmaceuticals, Inc., 20 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenon Pharmaceuticals, Inc. 51 out of 100 across roughly 4,600 US stocks as at 11 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XENE?

As at 11 Aug 2026, Xenon Pharmaceuticals, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (93 of 100).

Will XENE stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +26.6% from the last close, and Ticker Nerd's factor model ranks Xenon Pharmaceuticals, Inc. 51 out of 100 as at 11 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XENE stock forecast for 2030?

No analyst covering Xenon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XENE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $69 to $100 over the next 12 months.

How has XENE stock performed over the past year?

Xenon Pharmaceuticals, Inc. returned +85.3% over the 12 months to 11 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xenon Pharmaceuticals, Inc. do?

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for patients with neurological and psychiatric disorders.

What is the latest news on XENE?

The most recent item we track (Seeking Alpha, 11 Aug 2026): "Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity". Xenon Pharmaceuticals was upgraded to "Strong Buy" following positive phase 3 X-TOLE2 results for azetukalner in focal onset seizures. The company plans an NDA filing for azetukalner in FOS in Q3 2026, with X-TOLE3 supporting potential ex-US expansion, and phase 3 X-NOVA2 topline data for major depressive disorder expected in 1H 2027.

Company

About Xenon Pharmaceuticals, Inc.

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics for patients with neurological and psychiatric disorders. The company's lead molecule, azetukalner, is a novel potent selective Kv7 potassium channel opener currently in Phase 3 clinical trials for treating epilepsy, major depressive disorder, and bipolar depression. Xenon's pipeline also includes early-stage potassium and sodium channel modulators, with Kv7 and Nav1.7 programs in Phase 1 development for pain management. The company addresses areas of high unmet medical need in rare central nervous system conditions and other neurological disorders. Headquartered in Burnaby, British Columbia, with additional offices in Boston, Massachusetts, Xenon operates as a clinical-stage biopharmaceutical company committed to improving the lives of patients living with complex neurological conditions.

CEO Mr. Ian C. Mortimer C.M.A., CPA, M.B.A. · 358 employees · Canada · https://www.xenon-pharma.com